The purpose of this study is to develop transcranial magnetic stimulation (TMS) as a novel, non-pharmacologic approach to decreasing pain in individuals with chronic pain. This study will test whether rTMS over the prefrontal cortex can produce a reduction in your perception of pain, your desire to use opiates, and your brain's response to opiate cues. The results of this study will be used to design and develop a large clinical trial of rTMS as an innovative, new treatment option for chronic lower back pain in individuals that have used chronic opiates.
Transcranial direct current stimulation (tDCS) has shown the potential to improve symptoms in patients with Parkinson's disease, however its effects have not been consistent in randomized studies to date, limiting widespread adoption of this technology. A critical gap in our knowledge is a detailed understanding of how tDCS affects motor areas in the brain. We propose using tDCS while recording directly from motor cortex using subdural electrocorticography (sECoG) in Parkinson's patients undergoing deep brain stimulation surgery. We expect this novel approach to broaden our understanding of tDCS application in Parkinson's disease and possibly lead to therapeutic advances in this population.
This Charleston Alcohol Research Center (ARC) pilot study seeks to provide the preliminary validation of a novel natural rewards fMRI paradigm which may be used in the development and/or evaluation of alcohol addiction medication treatments. Specifically, individuals with alcohol use disorder (AUD) and social drinkers will be recruited for a magnetic resonance imaging (MRI) study which will include magnetic resonance spectroscopy, an alcohol cue task, and this novel natural rewards paradigm which examines brain response to social reward and food. Invited participants will complete an initial screening diagnostic assessment visit at the Medical University of South Carolina, which will consist of clinical interviews with research staff, questionnaires, and labs. If still eligible, participants will be invited for a second appointment which will include additional clinical measures, questionnaires, and an MRI scan. This study is confidential and participants will be compensated for participating.
The purpose of this research study is to understand the association between heart and brain health in a population of 40-75 year olds. In this study, we will work to better understand blood vessel stiffness and brain function in African American and non-Hispanic white individuals. You will be asked to give blood during the study visit. Additional information will be obtained to help the researcher better understand the blood vessel and brain function data collected. There is only one study visit that last roughly 2 hours and compensation will be available.
This study will assess patients with acute ischemic strokes being treated with n-Butylphthalide (NBP) softgel capsules. This is a phase II study to evaluate the safety of NBP treatment. The medication has the potential to reduce impairment of memory function, cerebral edema, and disruption of the blood-brain barrier.
MUSC is recruiting adult cigarette smokers (18 to 65) who are interested in participating in a research study examining the effects of brain stimulation on neural activity and behavior. This study consists of 2 visits over the course of 1-2 weeks. Qualified individuals will be compensated for participation. This research study is sponsored by MUSC but will physically take place at USC in Columbia, SC.
The purpose of this study is to develop repetitive transcranial magnetic stimulation (rTMS) as a potential treatment for nicotine addiction. Repetitive TMS is a non-invasive technique that uses magnetic pulses to temporarily stimulate specific brain areas in awake people (without the need for surgery, anesthetic, or other invasive procedures). This study will test whether rTMS over the forehead can produce a reduction in brain activity associated with craving that may prompt you to want to smoke cigarettes.
The purpose of this study is to understand how networks in the brain change over time. Participants will have 2 study visits (about 2 years apart) where they will undergo tests to assess mental function, fill out questionnaires, and undergo a brain MRI. At the first visit only, participants will also undergo a blood draw and a PET scan.
Participants are required to have a Co-Participant accompany them. This individual must be a reliable informant that has contact with the participant at least once per week.
The purpose of this study is to determine if giving the medicine "heparin" intravenously (through the veins) continuously for up to 14 days to subjects after a brain aneurysm has burst will help improve the chances of subjects having a good recovery after the bleed compared to subjects who get routine brain aneurysm care (standard of care). Patients who get routine care would also get heparin, but they would typically get an overall lower dose and the heparin would be injected under the skin (heparin shot) instead of in the veins.
The purpose of this study is to evaluate the potential mechanism of action and the safety of GET73, a new drug under development for the reduction of craving and drinking in alcohol dependent individuals. The study involves five to six visits over a three to four week period, including one to two assessment visits and two visits during which participants will be assigned to take, in a double-blinded fashion, both GET73 and a placebo (two visits during each condition). During three of these visits, participants will undergo a one-hour MRI scan. Compensation is available for qualified participants.